The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The futures Big
ANANDA DEVELOPMENTS PLC
Investor Presentation
14th Nov 2023 at 9:00am GMT
The RCT, funded by a £1.25m non-dilutive grant, is being led by Professor Marie Fallon a leading researcher at UofE. Professor Fallon is the St Columba's Hospice Chair of Palliative Medicine and Honorary Consultant in Palliative Care and has 256 publications and over 10,000 citations to her name. The trial will be a double-blind crossover trial, located at Western General Hospital with a 92?patient recruitment plan.
CIPN is a common and debilitating side effect of chemotherapy with approximately 160,000 new cases per year in the UK, with a prevalence 3 months after a chemotherapy treatment of 60%. There are no preventative treatments for CIPN, and symptomatic management is commonly ineffective. The CIPN global market was valued at US$1bn in 2021 and is estimated to reach US$1.5bn in 2030 and given most treatments are ineffective, the Directors believe that this figure does not accurately reflect the true market size.
Rationale for the research:
1. CIPN is a common condition and distressing to patients with no preventative options and no effective treatment to date.
2. Self-medication with cannabis is common, but clinical use lacks empirical evidence on efficacy and safety.
3. This research addresses calls from NICE and IASP (International Association for the Study of Pain) for cannabis-based medicine research. Following their reviews of the evidence, this research aligns with their recommendations for the choice of CBD and methodology (IASP) in CBD trials.
4. In addition, the trials are following guidelines for assessments in CIPN trials and have added mechanistic assessments.
5. There is strong preclinical evidence to match CIPN and CBD.
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
Drug Supply Agreement Signed
Today 07:00
RNS Number : 2934T
Ananda Developments PLC
14 November 2023
ANANDA DEVELOPMENTS PLC
("Ananda", the "Company" or the "Group")
Drug Supply Agreement Signed
Ananda Developments plc (AQSE: ANA), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions, is pleased to announce that its wholly owned subsidiary MRX Medical Limited ("MRX") has signed a Drug Supply Agreement ("DSA") with the University of Edinburgh ("UofE") and the Lothian Health Board ("LHB").
Highlights
· As announced on 9th March 2023, UofE and LHB are leading a Randomised Controlled Trial ("RCT") on the use of cannabidiol ("CBD") versus placebo in the treatment of chemotherapy induced peripheral neuropathic pain ("CIPN").
· MRX's patent pending MRX1 cannabidiol oil formulation will be used as the Investigative Medicinal Product ("IMP") in the trial. MRX is supplying the MRX1 CBD formulation and matched placebo.
· MRX has been granted a licence over all arising (generated from the trial) Intellectual Property ("IP") for internal research and development purposes, as well as an option to licence the arising IP for all commercial purposes. MRX will maintain full ownership of all IP as relates to the IMP and Placebo.
Ananda's CEO, Melissa Sturgess commented: "The drug supply agreement provides the legal framework for the provision of MRX1, our patent pending cannabinoid medicine, to the CIPN randomised controlled trial. Importantly it also confirms that MRX retains full IP ownership of the medicine and provides Ananda with a pathway to utilise the IP from the trial for commercial purposes. This will be a crucial part of Ananda's value if the trial is successful and the medicine is able to be commercialised via the NHS.
...
I've asked my quota I'm afraid. Though I will tune in and make notes.
Presentation tomorrow morning at 9am. I asked a question about potential relationships with HL and Traditum. I wanted to ask a question about what organised lobbying is taking place to open up NHS prescribing, too, but Investor Meet Company wouldn't allow me anymore questions. Is anyone planning on asking something like?
Well done Gazza
Forgot to say: Traditum is HLs PE partner.
According to Traditum PE's website, HL has a research partnership with Nottingham Trent University which specialises in medical cannabis testing and clinical trials. Traditum PE, Hilltop Leaf, Nottingham Trent Uni, and now Ananda's MOU with Nottingham Trent Uni? Speculation I know, but not without some subtance. Have a look at Traditum PEs website. There's a medicinal cannabis page in there.
Definitely DJ. Surely MS will be anticipating such, too. Can definitely see synergies. Unless HL is exporting its product, which its publicity says it isn't, where's all this medical cannabis going to go in the UK? Ananda seems to be saying current UK demand not consistent with its own production arm presently, yet HL and its PE partner North of the border seem to be going for it hammer and tongs. Would it be joining up too many dots to wish that Ananda are hoping for successful clinical trials in Edinburgh, an NHS breakthrough in Scotland (devolution and a more agile health improvement system), and a partnership with HL to stream some if that 10% UK demand to which HL has referred? I mean, it's a no-brainer in concept at least? And if they weren't or haven't considered this, at least as an option, you can't help thinking why on earth not?
Something we could perhaps ask at the upcoming Investor Pres, Pompey?
The big facility in Kent is GW Pharma owned. Not aware the Hilltop Leaf facility is pharma owned? It's brand new and its operational now, purporting to target 10% of UK demand. I suppose its purely coincidental the HL facility is completed at the same time as Ananda pauses its production programme. Perhaps we should ask ourselves this, too. Has HL and its PE partner put at least 2m into this venture on a speculative Scottish punt? That's a big facility and cash burn if nothings going out the door?
How do we know ANA haven't got their eye on Hilltop? Who knows, right?
Melissa did a short interview with Zak Mir the other day and in it she talked about 3 workstreams: seeds sales, plant genetics for future growing and the RCTs.
So whilst I can see your viewpoint re growing, it isn’t that work has stopped altogether but it has taken a change in direction. Instead of going it alone and needing to raise new funds, they are now partnering with Notts Uni, seeking grant funding and aiming to progress the genetics work that way.
Hilltop Leaf and a PE company recently completed a massive 11,000m2 medical canabis cultivation facility in Dumfries & Galloway, Scotland. Now operational, I believe. They're targeting supplying 10% of UK market, not for export (that's what theyre saying at any rate). Makes me wonder why Hilltop can get on with production but we can't seem to. Looking at recent rns too, the strategy has clearly moved away from horticulture to supplying medicines: no mention of production in rns opening gambits. Wonder if Ananda's going Scottish: Edinburgh CTs, and farm in the botanicals from Hilltop leaf. Could also benefit from different health improvement system up there, eg devolvement and no NICE tortoises? Go McAnanda!
RNS Number : 6884S
Ananda Developments PLC
08 November 2023
8 November 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Investor Presentation via Investor Meet Company
Ananda Developments Plc ('Ananda') is pleased to announce that Melissa Sturgess, Chief Executive Officer, will provide a live presentation update on Ananda via Investor Meet Company on Tuesday 14th November at 9:00am GMT. The presentation follows the Company's recent announcements and Investival Showcase presentation in London on Monday 13th November.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet ANANDA DEVELOPMENTS PLC via:
https://www.investormeetcompany.com/ananda-developments-plc/register-investor
Investors who already follow ANANDA DEVELOPMENTS PLC on the Investor Meet Company platform will automatically be invited.
The video will also be available for viewing after the event on the Company's website and YouTube channel (https://www.youtube.com/@anandadevelopmentsplc7440).
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
-Ends-
Another nice little announcement. All this adds to the gradually building business which will bear fruit long term.
As well as giving the Ananda story, Melissa is inviting questions from shareholders which she will answer during this presentation. Another great way to connect with shareholders.
'The application covers a new cannabinoid formulation known as MRX2T. This formulation is based on MRX's patent pending MRX2 cannabidiol formulation, with the addition of tetrahydrocannabinol (THC). This formulation has been developed for use in Randomised Controlled Trials (RCTs) and the Company looks forward to updating shareholders in due course.'
Https://www.lse.co.uk/rns/ANA.PL/thc-oil-patent-application-filed-dekadron7w61io7.html
Why don't both of you post at exactly the sane time and prove to these loons you are two different people? Honestly they're like flat earthers prattling on.
The Zak interview was really good. I hope 2024 will be a good year here.
I think your names spot on as you are a bit cookoo
I’ll say it again, we are different people. Why not join our Telegram group and then you might find out who we are. And you might just get a better insight into the company than you get from the few people who post here.
Oh yeah, and you never did answer either of my questions, so I’m still assuming you are here just to troll!